Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections

P Pfeiffer, P P Clausen, K Andersen, C Rose, P Pfeiffer, P P Clausen, K Andersen, C Rose

Abstract

The prognostic role of the epidermal growth factor receptor (EGFR) and the related receptor p185HER-2 in lung cancer is as yet undefined. We investigated the immunohistochemical expression of EGFR (monoclonal antibody R1; Amersham) and p185HER-2 (polyclonal antibody A485; Dako) in cryosections. A total of 186 unselected and systemically untreated patients with non-small-cell lung cancer (NSCLC) diagnosed and treated at Odense University Hospital, Denmark, were included. Median follow-up period was 66 months. EGFR and p185HER-2 was highly expressed in 55% and 26% of cases respectively. Expression of EGFR was independent of p185HER-2 expression. The expression of EGFR was higher in squamous cell carcinomas whereas the level of p185HER-2 staining was higher in adenocarcinomas. Expression of either or both receptors was not correlated with age, histological grading, stage and prognosis. We conclude that immunohistochemical detection of these growth factor receptors failed to demonstrate a prognostic significance in patients operated on for NSCLC.

References

    1. Cancer Res. 1990 Nov 1;50(21):7077-80
    1. Gene. 1995 Jun 14;159(1):19-27
    1. Br J Cancer. 1991 Oct;64(4):741-4
    1. Eur J Cancer. 1991;27(11):1372-5
    1. Anticancer Res. 1992 Jan-Feb;12(1):11-20
    1. Mol Carcinog. 1992;5(3):213-8
    1. J Cell Biochem. 1982;20(2):149-61
    1. J Clin Invest. 1984 Aug;74(2):647-51
    1. Br J Cancer. 1986 Aug;54(2):265-9
    1. Br J Cancer. 1987 May;55(5):513-6
    1. J Natl Cancer Inst. 1987 Sep;79(3):403-7
    1. J Pathol. 1987 Aug;152(4):297-307
    1. Cancer Res. 1989 Mar 1;49(5):1313-7
    1. Br J Cancer. 1989 May;59(5):746-9
    1. Cell. 1989 Jul 28;58(2):287-92
    1. J Surg Oncol. 1989 Sep;42(1):16-20
    1. Cancer Res. 1990 Jan 15;50(2):421-5
    1. Cancer Res. 1990 Aug 15;50(16):5184-7
    1. Anticancer Res. 1992 Jul-Aug;12(4):1183-7
    1. Prog Growth Factor Res. 1992;4(1):1-24
    1. Chest. 1993 Jan;103(1 Suppl):30S-34S
    1. J Endocrinol Invest. 1993 Feb;16(2):99-107
    1. Semin Oncol. 1993 Apr;20(2):105-27
    1. Cancer Res. 1993 May 15;53(10 Suppl):2379-85
    1. Clin Chim Acta. 1993 Apr 16;215(1):51-61
    1. Lancet. 1993 Jul 3;342(8862):19-21
    1. Br J Cancer. 1993 Jul;68(1):162-5
    1. J Cancer Res Clin Oncol. 1993;119(9):507-10
    1. N Engl J Med. 1994 Jan 20;330(3):153-8
    1. Anticancer Res. 1993 Nov-Dec;13(6A):2021-5
    1. J Thorac Cardiovasc Surg. 1994 Feb;107(2):590-5
    1. J Clin Invest. 1994 Feb;93(2):516-20
    1. J Natl Cancer Inst. 1994 May 4;86(9):673-80
    1. Anticancer Res. 1994 Jan-Feb;14(1B):261-7
    1. J Natl Cancer Inst. 1994 Jun 1;86(11):829-35
    1. Br J Cancer. 1994 Jun;69(6):979-85
    1. Br Med Bull. 1991 Jan;47(1):87-98

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere